Jiang 2018.

Methods	Study design: Randomised clinical trial Study duration: January 2015 to June 2016 Duration of follow‐up: 6 weeks Setting: Hospital
Participants	Inclusion criteria: Willing to sign a written informed consent document; diagnosed as HCC; Karnofsky score ≥ 60; life expectancy > 3 months; no history of interventional treatment; no obvious fistula Exclusion criteria: not suitable for TACE or MWA; with hepatic metastasis; with serious injuries of other organs; with abnormal haematopoietic function; with mental disorders; with concurrent other tumours Age (mean ± SD, range): TACE + MWA: 56.87 ± 12.70 years, 38‐71 years; TACE alone: 57.98 ± 13.05 years, 32‐74 years Male (n/total): TACE + MWA: 31/46; TACE alone: 28/46 Tumour diameter (mean ± SD, range): TACE + MWA: 6.97 ± 3.82 cm, 2. 50‐13. 27 cm; TACE: 7.32 ± 4.05 cm, 2. 58‐14. 19 cm. TNM stage (patients): Stage Ⅰ: TACE + MWA: 8; TACE: 7 Stage Ⅱ: TACE + MWA: 28; TACE: 26 Stage Ⅲ: TACE + MWA: 10; TACE: 13 Child‐Pugh Class (patients): Class A: TACE + MWA: 20; TACE: 22 Class B: TACE + MWA: 26; TACE: 24
Interventions	TACE + MWA group (n = 46): TACE: Chemotherapeutic drugs: oxaliplatin 130 mg/m2 and epirubicin 35 mg/m2. MWA: Ultrasound‐guided MWA. KV2000 system. Output power of 55 W and 6 minutes per MWA application TACE group (n = 46): Chemotherapeutic drugs: oxaliplatin 130 mg/m2 andepirubicin 35 mg/m2
Outcomes	Serum level of AFP: measured at 3 and 6 weeks after treatment; Serum level of VEGF: measured at 3 and 6 weeks after treatment; Immune function: measured at 3 and 6 weeks after treatment;
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.